多替拉韦钠+拉米夫定两药方案在初治HIV感染/AIDS患者的临床观察

doi:10.19871/j.cnki.xfcrbzz.2023.06.007

摘要/Abstract

摘要： 目的探讨多替拉韦钠（dolutegravir,DTG）+拉米夫定（lamivudine,3TC）简化方案在初治HIV感染/AIDS患者中的临床疗效。方法选取2019年1月至2022年9月期间在广西壮族自治区胸科医院接受抗反转录病毒治疗（antiretroviral therapy,ART）的初治HIV感染/AIDS患者,根据入组标准,观察组47例,采用DTG+3TC方案治疗;对照组49例,采用替诺福韦（tenofovir,TDF）+3TC+依非韦伦（efavirenz,EFV）方案治疗,观察比较两组治疗36周时HIV抑制率、免疫学情况。结果两组患者的基线特征中,年龄分布及基线HIV RNA载量差异具有统计学意义,其余基线指标未见明显差异;治疗12周,观察组及对照组病毒抑制率分别为56.6%、30.6%（P=0.011）;治疗24周,两组病毒抑制率分别为63.6%、79.6%（P=0.139）;治疗36周,两组病毒抑制率分别为85.1%和81.6%（P=0.786）,中位CD4⁺T淋巴细胞计数、CD4⁺/CD8⁺T淋巴细胞比值较于基线均明显升高,两组升高幅度无明显差异（P>0.05）。结论 DTG+3TC两药简化方案在治疗初治HIV感染/AIDS患者的病毒抑制效果与TDF+3TC+EFV三联疗法并无差别,甚至早期病毒抑制率优于TDF+3TC+EFV三药方案,同时能有效改善免疫功能。

关键词: 艾滋病, 拉米夫定, 多替拉韦钠, 两药方案, 临床疗效

Abstract: Objective To investigate the clinical efficacy of a simplified regimen of dolutegr-avir(DTG)+lamivudine(3TC) in first-treatment human immunodeficiency virus infection/acquired immure deficiency syndrome patients. Method Historical control subgroups were selected, and primary HIV/AIDS patients who received antiretroviral therapy（ART）at the Chest Hospital of Guangxi Zhuang Autonomous Region between January 2019 and September 2022 were selected. According to the enrolment criteria, 47 cases in the observation group were treated with DTG+3TC regimen, and 49 cases in the control group were treated with tenofovir (TDF) + lamivudine (3TC) + efavirenz (EFV) regimen, and the HIV suppression rate and immunological status of the two groups were compared with each other after 36 weeks of treatment under observation. Result In the baseline characteristics of the two groups, the difference in age distribution and baseline HIV RNA load capacity were statistically significant, with no significant difference in residual baseline index; at 12 week of treatment, the observation group and control group were 56.6% and 30.6%, respectively(P=0.011); at 24 weeks of treatment, the viral suppression rates of the two groups were 63.6% and 79.6%, respectively (P=0.139); at 36 weeks treatment, the viral suppression rates of the two groups were 85.1% and 81.6%,respectively(P=0.786), and the median CD4⁺T lymphocyte counts and CD4⁺/CD8⁺T lymphocyte ratios were significantly higher than those at baseline, and there was no significant difference in the magnitude of the increase between the two groups(P>0.05). Conclusion The viral suppression effect of the simplified two-drug regimen of DTG+3TC in the treatment of first-treatment HIV/AIDS patients was not different from that of the triple-drug regimen of TDF+3TC+EFV, and even the early viral suppression rate was better than that of the triple-drug regimen of TDF+3TC+EFV, and at the same time it could effectively improve immune function.

Key words: Acquired immure deficiency syndrome, Dolutegravir, Lamivudine, Two-drug regimen, Clinical efficacy

中图分类号:

R512.91

兰双来, 蓝珂, 张勇, 窦艳云. 多替拉韦钠+拉米夫定两药方案在初治HIV感染/AIDS患者的临床观察[J]. 新发传染病电子杂志, 2023, 8(6): 37-41.

Lan Shuanglai, Lan Ke, Zhang Yong, Dou Yangyun. Efficacy observation of the two-drug regimen DTG+3TC in treatment-naive human immunodeficiency virus infection/acquired Immure deficiency syndrome patients[J]. Electronic Journal of Emerging Infectious Diseases, 2023, 8(6): 37-41.

参考文献

[1] COLLINS SE, GRANT PM, SHAFER RW.Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients[J]. Drugs, 2016, 76(1):75-98.
[2] JAMIELYNN C, SEBAAL Y, DENISE K.HIV Clinical Updates: New Single-Tablet Regimens[J]. Ann Pharmacother, 2019, 53(1):82-94.
[3] BOSWELL R, FOISY MM, HUGHES CA.Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review[J]. Ann Pharmacother, 2018, 52(7):681-689.
[4] VITORIA M, HILL A, FORD N, et al.The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?[J].AIDS, 2018, 32(12):1551-1561.
[5] MICHAEL SS, CONSTANCE AB, RAJESH TG, et al.Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel[J]. JAMA, 2018, 320(4):379-396.
[6] WHO. WHO-Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance[EB/OL].[2018-12-14].https://www.who.int/hiv/pub/guidelines/ARV2018update/en/.
[7] EUROPEAN AIDS CLINICAL SOCIETY. the European Guidelines for the treatment of HIV-positive adults in Europe (version10.0)[EB/OL].[2023-01-10].https://www.eacsociety.org/guidelines/eacs-guidelines/eacs-guidelines.htmL2019.
[8] 中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心.中国艾滋病诊疗指南(2018版)[J/CD].新发传染病电子杂志,2019,4(2):65-84.
[9] MARTA B, FRANCOIS V.The triumph of HIV treatment: another new antiretroviral[J]. Lancet, 2017, 390(10107): 2019-2021.
[10] CAHN P, MADERO JS, ARRIBAS JR, et al.Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind,randomised, non-inferiority, phase 3 trials[J]. Lancet, 2019, 393(10167):143-155.
[11] CAHN P, MADERO JS, ARRIBAS JR, et al.Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials[J].Acquir Immune Defic Syndr, 2020, 83(3):310-318.
[12] 中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心. 中国艾滋病诊疗指南(2021年版)[J]. 中国艾滋病性病, 2021, 27(11):1182-1201.
[13] 凌雪梅, 蔡卫平, 钟活麟, 等. DTG+3TC简化方案真实世界临床疗效与安全性研究[J].传染病信息, 2022, 35(1):51-55.
[14] QUESADA PR, ESTEBAN LL, GARCIA JR, et al.Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients[J]. Int J Clin Pharm, 2015, 37(5): 865-872.
[15] LEE KH, KIM J, LEE JA,et al.Real-World Effectiveness, Tolerability, and Safety of Dolutegravir/Lamivudine in Korea[J]. Viruses, 2022, 14(11):2558.
[16] KOTEFF J, BORLAND J, CHEN S, et al.A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects[J]. Br J Clin Pharmacol, 2013, 75(4):990-996.
[17] BOURGI K, JENKINS CA, REBEIRO PF, et al.North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD).Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada[J].Int AIDS Soc, 2020, 23(4):e25484.
[18] BOURGI K, REBEIRO PF, TURNER M, et al.Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy[J]. Clin Infect Dis, 2020, 70(7):1267-1274.
[19] MENARD A, MEDDEB L, TISSOT-DUPONT H, et al.Dolutegravir and weight gain: an unexpected bothering side effect?[J].AIDS, 2017, 31(10):1499-1500.
[20] RIZZARDO S, LANZAFAME M, LATTUADA E, et al.Dolutegravir monotherapy and body weight gain in antiretroviral naïve patients[J].AIDS, 2019, 33(10):1673-1674.
[21] MAVE V, ERLANDSON KM, GUPTE N, et al.ACTG PEARLS and NWCS 319 Study Team.Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults[J].Infect Dis, 2016, 214(1):65-72.